SSTR2 and neoplasm: Radiolabeled SSTR2 antagonists, such as 177Lu-satoreotide tetraxetan, have shown higher tumor uptake, independent of SSTR activation, and greater tumor-to-organ ratios than agonists in preclinical models [160].